Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
28,511
Total Claims
$5.7M
Drug Cost
3,187
Beneficiaries
$1,800
Cost/Patient
Risk Score Breakdown 12/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+28%
Cost per patient vs peers
$1,800 vs $1,411 avg
+3%
Brand preference vs peers
11.0% vs 10.6% avg
Brand vs Generic
Brand: 3,123 claims · $4.9M
Generic: 25,288 claims · $843K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Rimegepant Sulfate | 755 | $1.3M |
| Ubrogepant | 384 | $550K |
| Pimavanserin Tartrate | 102 | $487K |
| Atogepant | 326 | $366K |
| Erenumab-Aooe | 314 | $274K |
| Galcanezumab-Gnlm | 318 | $230K |
| Deutetrabenazine | 15 | $229K |
| Diroximel Fumarate | 13 | $123K |
| Dimethyl Fumarate | 11 | $103K |
| Onabotulinumtoxina | 94 | $101K |
| Rivastigmine | 488 | $91K |
| Dextromethorphan Hbr/Quinidine | 68 | $89K |
| Valbenazine Tosylate | 11 | $83K |
| Memantine Hcl/Donepezil Hcl | 87 | $66K |
| Carbidopa/Levodopa | 68 | $64K |
Prescribing Profile
81
Unique Drugs
12.0
Anomaly Score
Patient Profile
72
Avg Age
65%
Female
2.17
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data